PPCB
Propanc Biopharma, Inc. Common StockPPCB
PPCB
About: Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Employees: 1
–
Funds holding %
of 7,376 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for PPCB.
Financial journalist opinion
Neutral
Seeking Alpha
2 days ago
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some small issuers may still price. Street research is expected for seven companies in the week ahead, and three lock-up periods will be expiring.
Neutral
GlobeNewsWire
3 days ago
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The offering is expected to yield approximately $4 million in gross proceeds before offering expenses and underwriting discounts and commissions.
Charts implemented using Lightweight Charts™